{"id":389863,"date":"2020-11-30T16:03:03","date_gmt":"2020-11-30T21:03:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389863"},"modified":"2020-11-30T16:03:03","modified_gmt":"2020-11-30T21:03:03","slug":"rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","title":{"rendered":"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Nov.  30, 2020  (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST.<\/p>\n<p>A live audio webcast will be available within the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V-993TBdBnDfxGZE5mlyTthdmwYBNIOMsuHPLRn0QKpwtRo6BaKVhZrkuWbBBeZNbpk_-qWBt7O5QduAP6kCUrug6FYGYK9v9u-nIn8GOQg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Investors &amp; Media<\/a> section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.<\/p>\n<p>\n        <strong>About\u00a0Rubius Therapeutics<\/strong>\n      <\/p>\n<p>Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary RED PLATFORM\u00ae\u00a0was designed to genetically engineer and culture Red Cell Therapeutics\u2122 that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius\u2019 initial focus is to advance RCT\u2122 product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities \u2014 potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jv7GC0tlGusKoJZCU9-jZPVqy3_IYlJ75-PBDx3HGsmc8zyCCjscsZFhWs6Er3oBQLYRtAvT7MS1sIixlYu7VA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.rubiustx.com<\/a>, follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j53fI2SCZZe_aAMx94TT7ia-_3tOJ5h4azJTFdCtRgyQUEhc-gytqCIaNa9rpAwBlv2hyApBySetN1QuxItWgw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ifyImU4b93e-UXiT7tPnls1z-pqnT_jZpMSrYCBgPP5_onpQS5Jgz3mn_mk0F1u2cvKz8bavN_GGak0AepJh371tjsmOcj-KbTV63zGE8iHi5ACbwt3A-pIiHUxYofwr\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>\u00a0or like us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RB2BznwoZIc2AAkJekeV3ffary31nNHua2setjMa8lIEeWRN8L_bUVZdgP8KLEjEzS2g5sWJhirf07vdNblRRw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Contacts: <\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Elhan Webb, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yg7Vln0iberR3p82ljquVkAiH1q2cJKeW_RdrUdROWoKxhZE_ZRoDVv1A76ogy1QomETflZiOaM0c7FPgWT7g3NPGKaG6HOOrr4AJ_7seCo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">elhan.webb@rubiustx.com<\/a><\/p>\n<p>\n        <strong>Media <\/strong><br \/>\n        <br \/>Marissa Hanify, Director, Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zEKosddM4eWWbeIRqwbE5SNLbnAQD6Mv9vwxocV55wbYSqDPCJGnPEseZYnJwqPlJZ4ZunaYpnxvcOuix9TXeqtQKa1LEwjXZ6AiwDjURw0OMNWlZOuCVVWTks8T-x7F\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Marissa.hanify@rubiustx.com<\/a><\/p>\n<p>Dan Budwick, 1AB<br \/>+1 (973) 271-6085<br \/>dan@1abmedia.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ed8069d9-7221-4b98-a461-1ddcf35b9642\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST. A live audio webcast will be available within the Investors &amp; Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About\u00a0Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389863","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST. A live audio webcast will be available within the Investors &amp; Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About\u00a0Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary &hellip; Continue reading &quot;Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T21:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference\",\"datePublished\":\"2020-11-30T21:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"name\":\"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=\",\"datePublished\":\"2020-11-30T21:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics\u2122, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST. A live audio webcast will be available within the Investors &amp; Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event. About\u00a0Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics\u2122. The Company\u2019s proprietary &hellip; Continue reading \"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T21:03:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference","datePublished":"2020-11-30T21:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/","name":"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=","datePublished":"2020-11-30T21:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5Mzk5MCMzODQ4NzQ2IzIxMjA3MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rubius-therapeutics-to-participate-in-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rubius Therapeutics to Participate in Evercore ISI\u00a03rd Annual\u00a0HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389863"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389863\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}